Affinity Asset Advisors LLC Sells 47,390 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Affinity Asset Advisors LLC lowered its holdings in NewAmsterdam Pharma (NASDAQ:NAMS) by 10.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 425,000 shares of the company’s stock after selling 47,390 shares during the quarter. NewAmsterdam Pharma comprises about 1.5% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 22nd largest position. Affinity Asset Advisors LLC owned 0.46% of NewAmsterdam Pharma worth $10,922,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. National Bank of Canada FI acquired a new stake in NewAmsterdam Pharma in the 4th quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $80,000. KLP Kapitalforvaltning AS bought a new position in NewAmsterdam Pharma in the 4th quarter worth approximately $154,000. Barclays PLC lifted its holdings in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after buying an additional 7,199 shares in the last quarter. Finally, HB Wealth Management LLC acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at $224,000. Institutional investors own 89.89% of the company’s stock.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. The trade was a 90.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James N. Topper purchased 4,005 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was acquired at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the transaction, the director now owns 3,012,434 shares of the company’s stock, valued at $63,321,362.68. This represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is owned by company insiders.

NewAmsterdam Pharma Trading Up 8.6 %

NAMS stock opened at $16.42 on Tuesday. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $27.29. The business’s 50 day simple moving average is $20.17 and its 200 day simple moving average is $21.30. The firm has a market capitalization of $1.80 billion, a PE ratio of -6.32 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $3.30 million. As a group, sell-side analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on NAMS shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research note on Monday, March 3rd. Needham & Company LLC reissued a “buy” rating and set a $42.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. Scotiabank lifted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.